
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7274326/publications.pdf Version: 2024-02-01



Τλέλομι Ομγικί

#	Article	IF	CITATIONS
1	Co-expression of nuclear heterogeneous nuclear ribonucleic protein K and estrogen receptor $\hat{I}\pm$ in endometrial cancer. Pathology Research and Practice, 2022, 231, 153795.	2.3	7
2	Immunolocalization of CD80 and CD86 in Non-Small Cell Lung Carcinoma: CD80 as a Potent Prognostic Factor. Acta Histochemica Et Cytochemica, 2022, 55, 25-35.	1.6	4
3	PSPC1 is a potential prognostic marker for hormone-dependent breast cancer patients and modulates RNA processing of ESR1 and SCFD2. Scientific Reports, 2022, 12, .	3.3	6
4	L-type amino acid transporter 1 is associated with chemoresistance in breast cancer via the promotion of amino acid metabolism. Scientific Reports, 2021, 11, 589.	3.3	27
5	Stromal CCL5 Promotes Breast Cancer Progression by Interacting with CCR3 in Tumor Cells. International Journal of Molecular Sciences, 2021, 22, 1918.	4.1	16
6	lsoforms of IDH in breast carcinoma: IDH2 as a potent prognostic factor associated with proliferation in estrogen-receptor positive cases. Breast Cancer, 2021, 28, 915-926.	2.9	10
7	Targeting Epigenetic and Posttranscriptional Gene Regulation by PSF Impairs Hormone Therapy–Refractory Cancer Growth. Cancer Research, 2021, 81, 3495-3508.	0.9	11
8	Functional inhibition of cancer stemness-related protein DPP4 rescues tyrosine kinase inhibitor resistance in renal cell carcinoma. Oncogene, 2021, 40, 3899-3913.	5.9	13
9	Subtype-specific collaborative transcription factor networks are promoted by OCT4 in the progression of prostate cancer. Nature Communications, 2021, 12, 3766.	12.8	20
10	Forkhead Box I1 in Breast Carcinoma as a Potent Prognostic Factor. Acta Histochemica Et Cytochemica, 2021, 54, 123-130.	1.6	8
11	Targeting Amino Acid Metabolic Reprogramming via L-Type Amino Acid Transporter 1 (LAT1) for Endocrine-Resistant Breast Cancer. Cancers, 2021, 13, 4375.	3.7	14
12	TRIM47 activates NF-κB signaling via PKC-ε/PKD3 stabilization and contributes to endocrine therapy resistance in breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	24
13	Wnt5a in cancer-associated fibroblasts promotes colorectal cancer progression. Biochemical and Biophysical Research Communications, 2021, 568, 37-42.	2.1	23
14	Identification and Functional Characterization of a Novel Androgen Receptor Coregulator, EAP1. Journal of the Endocrine Society, 2021, 5, bvab150.	0.2	4
15	Clinicopathological and Preclinical Patient-Derived Model Studies Define High Expression of NRN1 as a Diagnostic and Therapeutic Target for Clear Cell Renal Cell Carcinoma. Frontiers in Oncology, 2021, 11, 758503.	2.8	1
16	D-2-hydroxyglutarate dehydrogenase in breast carcinoma as a potent prognostic marker associated with proliferation. Histology and Histopathology, 2021, , 18362.	0.7	3
17	ALDH1A1 in patientâ€derived bladder cancer spheroids activates retinoic acid signaling leading to TUBB3 overexpression and tumor progression. International Journal of Cancer, 2020, 146, 1099-1113.	5.1	30
18	TRIM44 promotes cell proliferation and migration by inhibiting FRK in renal cell carcinoma. Cancer Science, 2020, 111, 881-890.	3.9	29

#	Article	IF	CITATIONS
19	Rac1 activation in human breast carcinoma as a prognostic factor associated with therapeutic resistance. Breast Cancer, 2020, 27, 919-928.	2.9	13
20	PSF Promotes ER-Positive Breast Cancer Progression via Posttranscriptional Regulation of <i>ESR1</i> and <i>SCFD2</i> . Cancer Research, 2020, 80, 2230-2242.	0.9	50
21	RNAâ€binding protein NONO promotes breast cancer proliferation by postâ€ŧranscriptional regulation of <i>SKP2</i> and <i>E2F8</i> . Cancer Science, 2020, 111, 148-159.	3.9	67
22	Hormonal Regulation of Patient-Derived Endometrial Cancer Stem-like Cells Generated by Three-Dimensional Culture. Endocrinology, 2019, 160, 1895-1906.	2.8	15
23	Cancerâ€associated fibroblasts secrete Wnt2 to promote cancer progression in colorectal cancer. Cancer Medicine, 2019, 8, 6370-6382.	2.8	55
24	A metabolic profile of routine needle biopsies identified tumor type specific metabolic signatures for breast cancer stratification: a pilot study. Metabolomics, 2019, 15, 147.	3.0	10
25	<i>ESR1</i> -Stabilizing Long Noncoding RNA <i>TMPO-AS1</i> Promotes Hormone-Refractory Breast Cancer Progression. Molecular and Cellular Biology, 2019, 39, .	2.3	46
26	Cytochrome c1 as a favorable prognostic marker in estrogen receptor-positive breast carcinoma. Histology and Histopathology, 2019, 34, 1365-1375.	0.7	4
27	COBLL1 modulates cell morphology and facilitates androgen receptor genomic binding in advanced prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 4975-4980.	7.1	21
28	TRIM25 enhances cell growth and cell survival by modulating p53 signals via interaction with G3BP2 in prostate cancer. Oncogene, 2018, 37, 2165-2180.	5.9	83
29	Association of USP10 with G3BP2 Inhibits p53 Signaling and Contributes to Poor Outcome in Prostate Cancer. Molecular Cancer Research, 2018, 16, 846-856.	3.4	74
30	The interplay of endocrine therapy, steroid pathways and therapeutic resistance: Importance of androgen in breast carcinoma. Molecular and Cellular Endocrinology, 2018, 466, 31-37.	3.2	10
31	<scp>OLFM</scp> 4, <scp>LY</scp> 6D and S100A7 as potent markers for distant metastasis in estrogen receptorâ€positive breast carcinoma. Cancer Science, 2018, 109, 3350-3359.	3.9	39
32	17β-Hydroxysteroid Dehydrogenase Type 2 Expression Is Induced by Androgen Signaling in Endometrial Cancer. International Journal of Molecular Sciences, 2018, 19, 1139.	4.1	13
33	Relaxin 2/RXFP1 Signaling Induces Cell Invasion via the β-Catenin Pathway in Endometrial Cancer. International Journal of Molecular Sciences, 2018, 19, 2438.	4.1	18
34	ARHGAP15 in Human Breast Carcinoma: A Potent Tumor Suppressor Regulated by Androgens. International Journal of Molecular Sciences, 2018, 19, 804.	4.1	16
35	In situ detection of estrogen receptor dimers in breast carcinoma cells in archival materials using proximity ligation assay (PLA). Journal of Steroid Biochemistry and Molecular Biology, 2017, 165, 159-169.	2.5	22
36	Aryl hydrocarbon receptor induced intratumoral aromatase in breast cancer. Breast Cancer Research and Treatment, 2017, 161, 399-407.	2.5	16

#	Article	IF	CITATIONS
37	Cytochrome c1 in ductal carcinoma <i>in situ</i> of breast associated with proliferation and comedo necrosis. Cancer Science, 2017, 108, 1510-1519.	3.9	14
38	p62/sequestosome 1 in human colorectal carcinoma as a potent prognostic predictor associated with cell proliferation. Cancer Medicine, 2017, 6, 1264-1274.	2.8	21
39	Associations of obesity and physical activity with serum and intratumoral sex steroid hormone levels among postmenopausal women with breast cancer: analysis of paired serum and tumor tissue samples. Breast Cancer Research and Treatment, 2017, 162, 115-125.	2.5	23
40	Dysregulation of spliceosome gene expression in advanced prostate cancer by RNA-binding protein PSF. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 10461-10466.	7.1	93
41	Retinoic Acid Receptor β: A Potential Therapeutic Target in Retinoic Acid Treatment of Endometrial Cancer. International Journal of Gynecological Cancer, 2017, 27, 643-650.	2.5	6
42	Interaction with adipocyte stromal cells induces breast cancer malignancy via S100A7 upregulation in breast cancer microenvironment. Breast Cancer Research, 2017, 19, 70.	5.0	37
43	Roles of Aryl Hydrocarbon Receptor in Aromatase-Dependent Cell Proliferation in Human Osteoblasts. International Journal of Molecular Sciences, 2017, 18, 2159.	4.1	19
44	Hexokinase 2 in colorectal cancer: a potent prognostic factor associated with glycolysis, proliferation and migration. Histology and Histopathology, 2017, 32, 351-360.	0.7	34
45	In situ androgen and estrogen biosynthesis in endometrial cancer: focus on androgen actions and intratumoral production. Endocrine-Related Cancer, 2016, 23, R323-R335.	3.1	24
46	<scp>CITED</scp> 2 in breast carcinoma as a potent prognostic predictor associated with proliferation, migration and chemoresistance. Cancer Science, 2016, 107, 1898-1908.	3.9	15
47	Human 3 β â€hydroxysteroid dehydrogenase type 1 in human breast cancer: clinical significance and prognostic associations. Cancer Medicine, 2016, 5, 1405-1415.	2.8	11
48	TACC2 (transforming acidic coiledâ€coil protein 2) in breast carcinoma as a potent prognostic predictor associated with cell proliferation. Cancer Medicine, 2016, 5, 1973-1982.	2.8	19
49	Steroid and xenobiotic receptor-mediated effects of bisphenol A on human osteoblasts. Life Sciences, 2016, 155, 29-35.	4.3	17
50	Intratumoral estrogen production and actions in luminal A type invasive lobular and ductal carcinomas. Breast Cancer Research and Treatment, 2016, 156, 45-55.	2.5	8
51	Abnormal expression of miRâ€I in breast carcinoma as a potent prognostic factor. Cancer Science, 2015, 106, 1642-1650.	3.9	20
52	11β-Prostaglandin F2α, a bioactive metabolite catalyzed by AKR1C3, stimulates prostaglandin F receptor and induces slug expression in breast cancer. Molecular and Cellular Endocrinology, 2015, 413, 236-247.	3.2	20
53	The role of 5α-reductase type 1 associated with intratumoral dihydrotestosterone concentrations in human endometrial carcinoma. Molecular and Cellular Endocrinology, 2015, 401, 56-64.	3.2	32
54	Increased androgen receptor activity and cell proliferation in aromatase inhibitor-resistant breast carcinoma. Journal of Steroid Biochemistry and Molecular Biology, 2014, 144, 513-522.	2.5	48

#	Article	IF	CITATIONS
55	GATA4 immunolocalization in breast carcinoma as a potent prognostic predictor. Cancer Science, 2014, 105, 600-607.	3.9	16
56	Cyclin-dependent kinase-specific activity predicts the prognosis of stage I and stage II non-small cell lung cancer. BMC Cancer, 2014, 14, 755.	2.6	7
57	Immunolocalization of Corticotropin-Releasing Hormone (CRH) and Its Receptors (CRHR1 and CRHR2) in Human Endometrial Carcinoma. International Journal of Gynecological Cancer, 2014, 24, 1549-1557.	2.5	13
58	NRF2 immunolocalization in human breast cancer patients as a prognostic factor. Endocrine-Related Cancer, 2014, 21, 241-252.	3.1	55
59	Tissue concentrations of estrogens and aromatase immunolocalization in interstitial pneumonia of human lung. Molecular and Cellular Endocrinology, 2014, 392, 136-143.	3.2	12
60	Intratumoral androgen metabolism and actions in invasive lobular carcinoma of the breast. Cancer Science, 2014, 105, 1503-1509.	3.9	9
61	Expression of (pro)renin receptor in breast cancers and its effect on cancercell proliferation. Biomedical Research, 2014, 35, 117-126.	0.9	25
62	Intratumoral localization and activity of 17β-hydroxysteroid dehydrogenase type 1 in non-small cell lung cancer: a potent prognostic factor. Journal of Translational Medicine, 2013, 11, 167.	4.4	21
63	BUB1 Immunolocalization in Breast Carcinoma: Its Nuclear Localization as a Potent Prognostic Factor of the Patients. Hormones and Cancer, 2013, 4, 92-102.	4.9	34
64	Androgen and androgen-metabolizing enzymes in metastasized lymph nodes of breast cancer. Human Pathology, 2013, 44, 2338-2345.	2.0	12
65	Androgen-responsive long noncoding RNA CTBP1-AS promotes prostate cancer. EMBO Journal, 2013, 32, 1665-1680.	7.8	243
66	Amyloid precursor protein in human breast cancer: An androgenâ€induced gene associated with cell proliferation. Cancer Science, 2013, 104, 1532-1538.	3.9	51
67	Intratumoral Estrogen Concentration and Expression of Estrogen-Induced Genes in Male Breast Carcinoma: Comparison with Female Breast Carcinoma. Hormones and Cancer, 2013, 4, 1-11.	4.9	13
68	Immunohistochemical analysis of aromatase in metastatic lymph nodes of breast cancer. Pathology International, 2013, 63, 20-28.	1.3	5
69	Androgenic pathway in triple negative invasive ductal tumors: Its correlation with tumor cell proliferation. Cancer Science, 2013, 104, 639-646.	3.9	71
70	Novel prognostic protein markers of resectable pancreatic cancer identified by coupled shotgun and targeted proteomics using formalinâ€fixed paraffinâ€embedded tissues. International Journal of Cancer, 2013, 132, 1368-1382.	5.1	74
71	Hexokinase <scp>II</scp> in breast carcinoma: A potent prognostic factor associated with hypoxiaâ€inducible factorâ€1α and <scp>K</scp> iâ€67. Cancer Science, 2013, 104, 1380-1388.	3.9	59
72	Krüppel-like factor 5 in human breast carcinoma: a potent prognostic factor induced by androgens. Endocrine-Related Cancer, 2012, 19, 741-750.	3.1	39

#	Article	IF	CITATIONS
73	TACC2 Is an Androgen-Responsive Cell Cycle Regulator Promoting Androgen-Mediated and Castration-Resistant Growth of Prostate Cancer. Molecular Endocrinology, 2012, 26, 748-761.	3.7	45
74	Oestrogen-induced genes in ductal carcinoma in situ: their comparison with invasive ductal carcinoma. Endocrine-Related Cancer, 2012, 19, 485-496.	3.1	11
75	An induction of microRNA, miR-7 through estrogen treatment in breast carcinoma. Journal of Translational Medicine, 2012, 10, S2.	4.4	32
76	Aromatase inhibitor treatment of breast cancer cells increases the expression of <i>letâ€7f</i> , a microRNA targeting <i>CYP19A1</i> . Journal of Pathology, 2012, 227, 357-366.	4.5	73
77	Runtâ€related transcription factor 2 in human colon carcinoma: A potent prognostic factor associated with estrogen receptor. International Journal of Cancer, 2012, 131, 2284-2293.	5.1	53
78	Nucleobindin 2 in human breast carcinoma as a potent prognostic factor. Cancer Science, 2012, 103, 136-143.	3.9	59
79	Accumulation of p62/ <scp>SQSTM</scp> 1 is associated with poor prognosis in patients with lung adenocarcinoma. Cancer Science, 2012, 103, 760-766.	3.9	177
80	Estrogen Regulates Tumor Growth Through a Nonclassical Pathway that Includes the Transcription Factors ERÎ <sup>2</sup> and KLF5. Science Signaling, 2011, 4, ra22.	3.6	92
81	Steroid sulfatase and estrogen sulfotransferase in human carcinomas. Molecular and Cellular Endocrinology, 2011, 340, 148-153.	3.2	36
82	Retinoid receptors in human esophageal squamous cell carcinoma: Retinoid X receptor as a potent prognostic factor. Pathology International, 2011, 61, 401-408.	1.3	5
83	Increased 5α-Reductase Type 2 Expression in Human Breast Carcinoma following Aromatase Inhibitor Therapy: The Correlation with Decreased Tumor Cell Proliferation. Hormones and Cancer, 2011, 2, 73-81.	4.9	24
84	Nudixâ€ŧype motif 2 in human breast carcinoma: A potent prognostic factor associated with cell proliferation. International Journal of Cancer, 2011, 128, 1770-1782.	5.1	37
85	Androgens in human breast carcinoma. Medical Molecular Morphology, 2010, 43, 75-81.	1.0	36
86	Increased estrogen sulfatase (STS) and 17β-hydroxysteroid dehydrogenase type 1(17β-HSD1) following neoadjuvant aromatase inhibitor therapy in breast cancer patients. Breast Cancer Research and Treatment, 2010, 120, 639-648.	2.5	44
87	Steroid and xenobiotic receptor in human esophageal squamous cell carcinoma: A potent prognostic factor. Cancer Science, 2010, 101, 543-549.	3.9	19
88	Immunolocalization of estrogenâ€producing and metabolizing enzymes in benign breast disease: Comparison with normal breast and breast carcinoma. Cancer Science, 2010, 101, 2286-2292.	3.9	23
89	Increased intratumoral androgens in human breast carcinoma following aromatase inhibitor exemestane treatment. Endocrine-Related Cancer, 2010, 17, 415-430.	3.1	64
90	Intratumoral Localization of Aromatase and Interaction between Stromal and Parenchymal Cells in the Non–Small Cell Lung Carcinoma Microenvironment. Cancer Research, 2010, 70, 6659-6669.	0.9	49

#	Article	IF	CITATIONS
91	The AP-1 family member FOS blocks transcriptional activity of the nuclear receptor steroidogenic factor 1. Journal of Cell Science, 2010, 123, 3956-3965.	2.0	21
92	Highly concordant coexpression of aromatase and estrogen receptor β in non–small cell lung cancer. Human Pathology, 2010, 41, 190-198.	2.0	61
93	Aromatase and in situ estrogen production in DCIS (ductal carcinoma in situ) of human breast. Journal of Steroid Biochemistry and Molecular Biology, 2010, 118, 242-245.	2.5	10
94	17β-Hydroxysteroid Dehydrogenase Type 12 in Human Breast Carcinoma: A Prognostic Factor via Potential Regulation of Fatty Acid Synthesis. Cancer Research, 2009, 69, 1392-1399.	0.9	36
95	Development of the human adrenal zona reticularis: morphometric and immunohistochemical studies from birth to adolescence. Journal of Endocrinology, 2009, 203, 241-252.	2.6	71
96	Amyloid Precursor Protein Is a Primary Androgen Target Gene That Promotes Prostate Cancer Growth. Cancer Research, 2009, 69, 137-142.	0.9	105
97	Steroid Sulfatase and Estrogen Sulfotransferase in Colon Carcinoma: Regulators of Intratumoral Estrogen Concentrations and Potent Prognostic Factors. Cancer Research, 2009, 69, 914-922.	0.9	56
98	<i>In situ</i> estrogen production and its regulation in human breast carcinoma: From endocrinology to intracrinology. Pathology International, 2009, 59, 777-789.	1.3	80
99	Adrenal changes associated with adrenarche. Reviews in Endocrine and Metabolic Disorders, 2009, 10, 19-26.	5.7	74
100	Chicken ovalbumin upstream promoter transcription factor II in human breast carcinoma: Possible regulator of lymphangiogenesis via vascular endothelial growth factor  expression. Cancer Science, 2009, 100, 639-645.	3.9	36
101	17βâ€Hydroxysteroid Dehydrogenases in Human Breast Cancer. Annals of the New York Academy of Sciences, 2009, 1155, 25-32.	3.8	28
102	New Developments in Intracrinology of Human Breast Cancer. Annals of the New York Academy of Sciences, 2009, 1155, 76-79.	3.8	28
103	Intracrinology of sex steroids in ductal carcinoma in situ (DCIS) of human breast: Comparison to invasive ductal carcinoma (IDC) and non-neoplastic breast. Journal of Steroid Biochemistry and Molecular Biology, 2009, 114, 68-71.	2.5	19
104	Comparative effects of raloxifene, tamoxifen and estradiol on human osteoblasts in vitro: Estrogen receptor dependent or independent pathways of raloxifene. Journal of Steroid Biochemistry and Molecular Biology, 2009, 113, 281-289.	2.5	26
105	Intratumoral estrogen production in breast carcinoma: significance of aromatase. Breast Cancer, 2008, 15, 270-277.	2.9	28
106	Sex steroid receptors expression and hormoneâ€induced cell proliferation in human osteosarcoma. Cancer Science, 2008, 99, 518-523.	3.9	44
107	Intracrinology of estrogens and androgens in breast carcinoma. Journal of Steroid Biochemistry and Molecular Biology, 2008, 108, 181-185.	2.5	73
108	Intratumoral Estrogens and Estrogen Receptors in Human Non–Small Cell Lung Carcinoma. Clinical Cancer Research, 2008, 14, 4417-4426.	7.0	179

#	Article	IF	CITATIONS
109	Intratumoral concentration of sex steroids and expression of sex steroid-producing enzymes in ductal carcinoma in situ of human breast. Endocrine-Related Cancer, 2008, 15, 113-124.	3.1	70
110	Aromatase in Human Breast Carcinoma as a Key Regulator of Intratumoral Sex Steroid Concentrations. Endocrine Journal, 2008, 55, 455-463.	1.6	32
111	Early growth responsive gene 3 in human breast carcinoma: a regulator of estrogen-meditated invasion and a potent prognostic factor. Endocrine-Related Cancer, 2007, 14, 279-292.	3.1	49
112	New development in intracrinology of breast carcinoma: therapeutic horizons after aromatase inhibitors. Expert Review of Endocrinology and Metabolism, 2007, 2, 367-374.	2.4	0
113	Aromatase Localization in Human Breast Cancer Tissues: Possible Interactions between Intratumoral Stromal and Parenchymal Cells. Cancer Research, 2007, 67, 3945-3954.	0.9	117
114	Effects of aromatase inhibitors on human osteoblast and osteoblast-like cells: A possible androgenic bone protective effects induced by exemestane. Bone, 2007, 40, 876-887.	2.9	46
115	Controversies of aromatase localization in human breast cancer—Stromal versus parenchymal cells. Journal of Steroid Biochemistry and Molecular Biology, 2007, 106, 97-101.	2.5	27
116	5α-Reductase type 1 and aromatase in breast carcinoma as regulators ofin situ androgen production. International Journal of Cancer, 2007, 120, 285-291.	5.1	71
117	Benign cortisol-secreting adrenocortical adenomas produce small amounts of androgens. Clinical Endocrinology, 2007, 66, 778-788.	2.4	19
118	Nuclear cyclin B1 in human breast carcinoma as a potent prognostic factor. Cancer Science, 2007, 98, 644-651.	3.9	91
119	Human liverâ€specific organic anion transporterâ€2 is a potent prognostic factor for human breast carcinoma. Cancer Science, 2007, 98, 1570-1576.	3.9	83
120	Ovarian epithelial carcinoma with estrogen-producing stroma. Pathology International, 2007, 57, 285-290.	1.3	19
121	In situ production of sex steroids in human breast carcinoma. Medical Molecular Morphology, 2007, 40, 121-127.	1.0	34
122	Immunolocalization of liver receptor homologue-1 (LRH-1) in human breast carcinoma: Possible regulator of in situ steroidogenesis. Cancer Letters, 2006, 244, 24-33.	7.2	52
123	17β-Hydroxysteroid dehydrogenases in human endometrium and its disorders. Molecular and Cellular Endocrinology, 2006, 248, 136-140.	3.2	50
124	Steroid sulfatase and estrogen sulfotransferase in human prostate cancer. Prostate, 2006, 66, 1005-1012.	2.3	55
125	Progesterone receptor isoforms as a prognostic marker in human endometrial carcinoma. Cancer Science, 2006, 97, 1308-1314.	3.9	36
126	New development in intracrinology of breast carcinoma. Breast Cancer, 2006, 13, 129-136.	2.9	86

#	Article	IF	CITATIONS
127	Expression of the Steroid and Xenobiotic Receptor and Its Possible Target Gene, Organic Anion Transporting Polypeptide-A, in Human Breast Carcinoma. Cancer Research, 2006, 66, 535-542.	0.9	132
128	Inflammatory Mediators Down-Regulate 11.BETAHydroxysteroid Dehydrogenase Type 2 in a Human Lung Epithelial Cell Line BEAS-2B and the Rat Lung. Tohoku Journal of Experimental Medicine, 2005, 207, 293-301.	1.2	16
129	In situ androgen producing enzymes in human prostate cancer. Endocrine-Related Cancer, 2005, 12, 101-107.	3.1	84
130	Progesterone Receptor in Non–Small Cell Lung Cancer—A Potent Prognostic Factor and Possible Target for Endocrine Therapy. Cancer Research, 2005, 65, 6450-6458.	0.9	153
131	Urocortin 1, Urocortin 3/Stresscopin, and Corticotropin-Releasing Factor Receptors in Human Adrenal and Its Disorders. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 4671-4678.	3.6	43
132	Estrogen-Responsive Finger Protein as a New Potential Biomarker for Breast Cancer. Clinical Cancer Research, 2005, 11, 6148-6154.	7.0	65
133	Steroid Sulfotransferase 2A1 Gene Transcription Is Regulated by Steroidogenic Factor 1 and GATA-6 in the Human Adrenal. Molecular Endocrinology, 2005, 19, 184-197.	3.7	56
134	Transcriptional Regulation of Dehydroepiandrosterone Sulfotransferase (SULT2A1) by Estrogen-Related Receptor α. Endocrinology, 2005, 146, 3605-3613.	2.8	47
135	Analysis for Localization of Steroid Sulfatase in Human Tissues. Methods in Enzymology, 2005, 400, 303-316.	1.0	9
136	Estrogen Inhibits Cell Proliferation through In situ Production in Human Thymoma. Clinical Cancer Research, 2005, 11, 6495-6504.	7.0	12
137	Sex steroid-producing enzymes in human breast cancer. Endocrine-Related Cancer, 2005, 12, 701-720.	3.1	156
138	Analysis of gene expression induced by diethylstilbestrol (DES) in human primitive Müllerian duct cells using microarray. Cancer Letters, 2005, 220, 197-210.	7.2	10
139	Interactions between prostaglandin E(2), liver receptor homologue-1, and aromatase in breast cancer. Cancer Research, 2005, 65, 657-63.	0.9	75
140	Nur-Related Factor 1 and Nerve Growth Factor-Induced Clone B in Human Adrenal Cortex and Its Disorders. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 4113-4118.	3.6	42
141	Estrogen-Related Receptor α in Human Breast Carcinoma as a Potent Prognostic Factor. Cancer Research, 2004, 64, 4670-4676.	0.9	200
142	Steroid Sulfatase and Estrogen Sulfotransferase in Human Endometrial Carcinoma. Clinical Cancer Research, 2004, 10, 5850-5856.	7.0	81
143	The Orphan Nuclear Receptor NGFIB Regulates Transcription of 3β-Hydroxysteroid Dehydrogenase. Journal of Biological Chemistry, 2004, 279, 37622-37630.	3.4	113
144	Systemic distribution of estrogen-responsive finger protein (Efp) in human tissues. Molecular and Cellular Endocrinology, 2004, 218, 147-153.	3.2	17

#	Article	IF	CITATIONS
145	Ductal carcinomain situ and related lesions of the breast: Recent advances in pathology practice. Breast Cancer, 2004, 11, 325-333.	2.9	7
146	Sex steroid receptors in rheumatoid arthritis. Clinical Science, 2004, 106, 293-300.	4.3	59
147	Increased expression of 11beta-hydroxysteroid dehydrogenase type 2 in the lungs of patients with acute respiratory distress syndrome. Pathology International, 2003, 53, 751-756.	1.3	18
148	Effects of steroid hormones on vascular functions. Microscopy Research and Technique, 2003, 60, 76-84.	2.2	50
149	Steroid Sulfatase and Estrogen Sulfotransferase in the Atherosclerotic Human Aorta. American Journal of Pathology, 2003, 163, 1329-1339.	3.8	40
150	Intracrine mechanism of estrogen synthesis in breast cancer. Biomedicine and Pharmacotherapy, 2003, 57, 460-462.	5.6	34
151	Steroid sulfatase and estrogen sulfotransferase in normal human tissue and breast carcinoma. Journal of Steroid Biochemistry and Molecular Biology, 2003, 86, 449-454.	2.5	64
152	Role of Local 11β-Hydroxysteroid Dehydrogenase Type 2 Expression in Determining the Phenotype of Adrenal Adenomas. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 864-870.	3.6	21
153	Estrogen sulfotransferase and steroid sulfatase in human breast carcinoma. Cancer Research, 2003, 63, 2762-70.	0.9	146
154	Progesterone Metabolism in Human Leukemic Monoblast U937 Cells Endocrine Journal, 2002, 49, 539-546.	1.6	11
155	Systemic Distribution of Steroid Sulfatase and Estrogen Sulfotransferase in Human Adult and Fetal Tissues. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 5760-5768.	3.6	156
156	Dissecting human adrenal androgen production. Trends in Endocrinology and Metabolism, 2002, 13, 234-239.	7.1	260
157	In situ production of estrogens in human breast carcinoma. Breast Cancer, 2002, 9, 296-302.	2.9	21
158	Expression of Urocortin and Corticotropin-Releasing Factor Receptor Subtypes in the Human Heart. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 340-346.	3.6	40
159	Immunohistochemical distribution of 11β-hydroxysteroid dehydrogenase in human eye. Molecular and Cellular Endocrinology, 2001, 173, 121-125.	3.2	38
160	Retinoid Receptors in Human Breast Carcinoma: Possible Modulators of in Situ Estrogen Metabolism. Breast Cancer Research and Treatment, 2001, 65, 31-40.	2.5	29
161	The Analyses of 17β-Hydroxysteroid Dehydrogenase Isozymes in Human Endometrial Hyperplasia and Carcinoma1. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 3436-3443.	3.6	46
162	Urocortin and Corticotropin-Releasing Factor Receptor Expression in Normal Cycling Human Ovaries <sup>1</sup> . Journal of Clinical Endocrinology and Metabolism, 2001, 86, 1362-1369.	3.6	56

#	Article	IF	CITATIONS
163	5α-Reductases in Human Breast Carcinoma: Possible Modulator ofin SituAndrogenic Actions1. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 2250-2257.	3.6	61
164	Developmental changes in steroidogenic enzymes in human postnatal adrenal cortex: immunohistochemical studies. Clinical Endocrinology, 2000, 53, 739-747.	2.4	176
165	17β-Hydroxysteroid Dehydrogenase Type 1 and 2 Expression in the Human Fetus1. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 410-416.	3.6	37
166	11β-Hydroxysteroid Dehydrogenase Type II and Mineralocorticoid Receptor in Human Placenta1. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 1306-1309.	3.6	32
167	11β-Hydroxysteroid Dehydrogenase Type 2 and Mineralocorticoid Receptor in Human Fetal Development. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 1453-1458.	3.6	31
168	Messenger Ribonucleic Acidin SituHybridization Analysis of Estrogen Receptors α and β in Human Breast Carcinoma1. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 781-785.	3.6	34
169	Superoxide dismutase in normal cycling human ovaries: immunohistochemical localization and characterization. Fertility and Sterility, 1999, 72, 720-726.	1.0	98
170	17β-Hydroxysteroid Dehydrogenase Types 1 and 2 in Human Placenta: An Immunohistochemical Study with Correlation to Placental Development <sup>1</sup> . Journal of Clinical Endocrinology and Metabolism, 1998, 83, 3710-3715.	3.6	51
171	11β-Hydroxysteroid Dehydrogenase Type 2 in Human Lung: Possible Regulator of Mineralocorticoid Action. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 4022-4025.	3.6	48
172	Colocalization of 11β-Hydroxysteroid Dehydrogenase Type II and Mineralocorticoid Receptor in Human Epithelia. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 3859-3863.	3.6	75
173	Localization of Steroidogenesis and Steroid Receptors in Human Corpus Luteum. Seminars in Reproductive Medicine, 1997, 15, 345-352.	1.1	30
174	Physiology: Immunohistochemical distribution of progesterone, androgen and oestrogen receptors in the human ovary during the menstrual cycle: relationship to expression of steroidogenic enzymes. Human Reproduction, 1994, 9, 1589-1595.	0.9	162